CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 130 enrolled
Drug / intervention
180mg of ETC-1002(bempedoic acid)drug
Likely dose
180mg of ETC-1002(bempedoic acid)from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05687071
NCT05687071Phase 3Completed
CompareCT.gov

A Multicenter, Open-label, Uncontrolled, Long-term Trial to Assess the Safety and Efficacy of ETC-1002 in Patients With Hyper-LDL Cholesterolemia

Otsuka Pharmaceutical Co., Ltd.·interventional·Posted Jan 17, 2023·Updated Feb 20, 2026

In Brief

A Phase 3 clinical trial evaluating 180mg of ETC-1002(bempedoic acid) for Hyper-low-density Lipoprotein (LDL) Cholesterolemia. Completed, enrolled 130 participants across 1 site.

Detailed Summary

A Multicenter, Open-label Study to assess the safety and efficacy of ETC-1002 at 180 mg administered for 52 weeks in patients with hyper-LDL cholesterolemia

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHyper-low-density Lipoprotein (LDL) Cholesterolemia
CountriesJapan
Collaborators--

Timeline

Phase 3CompletedFinished
2023202420252026
First PostedJan 17, 2023
Enrollment StartFeb 27, 2023
Primary CompletionOct 5, 2024
Study CompletionNov 2, 2024
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 3.5 years ago

Interventions

180mg of ETC-1002(bempedoic acid)drug

180mg, tablet, once daily, for 52 weeks